Bristol-Myers Squibb Company
Bristol Myers Squibb Reports 2025 Financial Results and Announces Dividend Increase
Summary
Bristol Myers Squibb reported its financial results for the fourth quarter and full year of 2025, showing a 1% increase in total revenues to $12.5 billion and a significant rise in GAAP EPS from $0.04 to $0.53. The company's Growth Portfolio revenues increased by 16% to $7.4 billion, driven by strong performance in immuno-oncology products. Bristol Myers also announced an increase in its quarterly dividend to $0.63 per share, marking the 17th consecutive annual increase. The company provided financial guidance for 2026, expecting total revenues between $46.0 and $47.5 billion. Additionally, BMY announced a strategic partnership with Microsoft aimed at accelerating the early detection of lung cancer.
Profitelligence Alerts
Get alerts for BMY
Be first to know when Bristol-Myers Squibb Company files with the SEC.
Filing Categories
Advertisement
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is a renowned pharmaceutical corporation engaged in the discovery, development, and distribution of innovative medicines. The company's core focus lies in providing therapeutic solutions for areas such as oncology, immunology, cardiovascular disease, and fibrotic diseases. Founded in 1887 and headquartered in New York City, it has grown into a key player in the global healthcare market, influencing medical advancements and treatment protocols. Bristol-Myers Squibb is pivotal for its groundbreaking contributions to cancer treatment, particularly through its development of immunotherapy drugs, which alter and assist the immune system's ability to fight cancer cells. Additionally, the firm extends its impacts across multiple sectors, affecting industries such as biotechnology, pharmaceuticals, and healthcare. The company's significance is underscored by its extensive research and development investments, often collaborating with research institutions and academic entities worldwide to pioneer new treatments. Such collaborations expand its influence beyond product distribution to shaping future healthcare landscapes. Bristol-Myers Squibb's commitment to innovation and addressing unmet medical needs makes it a prominent entity in the pharmaceutical sector.
Official SEC Documents
Advertisement